ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025
Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in chronic obstructive pulmonary disease: A systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.The Journal of international medical research · 2026Pooled it
- Cardiovascular Risk During the 90-Day Vulnerable Window After COPD Exacerbations: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Review
- Real-World Impact of Initial Dual Bronchodilation on Exercise Physiological Response and Health-Related Quality of Life in Newly Diagnosed, Treatment-Naïve Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2026Article
- The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Mortality trends and disparities in older U.S. adults with atrial fibrillation and COPD: a 1999-2020 CDC WONDER analysis with forecast to 2030.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-blockers are a fundamental component of cardiovascular disease (CVD) management, while β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.